The future of CTCL therapy

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, shares her views on the future of cutaneous T-cell lymphoma (CTCL) therapy, highlighting the unmet need for more efficacious therapies and to determine the optimal sequencing of therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

• فئة